These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Sun L; Cai J; Gonzalez FJ Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795 [TBL] [Abstract][Full Text] [Related]
7. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816 [TBL] [Abstract][Full Text] [Related]
8. Progress and challenges of selective Farnesoid X Receptor modulation. Massafra V; Pellicciari R; Gioiello A; van Mil SWC Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033 [TBL] [Abstract][Full Text] [Related]
9. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182 [TBL] [Abstract][Full Text] [Related]
10. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894 [TBL] [Abstract][Full Text] [Related]
11. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development. Tang Y; Fan Y; Wang Y; Wang D; Huang Q; Chen T; Cao X; Wen C; Shen X; Li J; You Y Biomed Pharmacother; 2024 Jun; 175():116658. PubMed ID: 38701562 [TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. Fang Y; Hegazy L; Finck BN; Elgendy B J Med Chem; 2021 Dec; 64(24):17545-17571. PubMed ID: 34889100 [TBL] [Abstract][Full Text] [Related]
13. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease. van Zutphen T; Bertolini A; de Vries HD; Bloks VW; de Boer JF; Jonker JW; Kuipers F Handb Exp Pharmacol; 2019; 256():207-234. PubMed ID: 31236687 [TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. Halilbasic E; Fuchs C; Traussnigg S; Trauner M Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721 [TBL] [Abstract][Full Text] [Related]
15. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. Xiang D; Yang J; Liu L; Yu H; Gong X; Liu D Biomed Pharmacother; 2023 Dec; 168():115606. PubMed ID: 37812893 [TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor modulators: a patent review. Crawley ML Expert Opin Ther Pat; 2010 Aug; 20(8):1047-57. PubMed ID: 20569093 [TBL] [Abstract][Full Text] [Related]
18. Tissue-specific function of farnesoid X receptor in liver and intestine. Zhu Y; Li F; Guo GL Pharmacol Res; 2011 Apr; 63(4):259-65. PubMed ID: 21211565 [TBL] [Abstract][Full Text] [Related]
19. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro. Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435 [TBL] [Abstract][Full Text] [Related]
20. Discovery of farnesoid X receptor and its role in bile acid metabolism. Chiang JYL; Ferrell JM Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]